CD4+ T cell anergy in transplantation tolerance requires continuous Treg-dependent control of IL-2 availability
Journal of Clinical Investigation · 19.11.2026
DOI: 10.1172/jci206638 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 19.11.2026. Verfasst von Alexandra Cassano und 12 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID, NIH, American Heart Association.
Abstract (Originalsprache)
Donor-specific transplantation tolerance promises to free recipients from complications associated with lifelong immunosuppression. Anergy, a CD4 + conventional T cell (Tconv)-intrinsic state of long-term hypofunction, is thought to arise when T cells encounter cognate antigen in the absence of costimulation. Anti-CD154 (αCD154), an antibody that blocks T cell costimulation and is currently in clinical trials, can induce donor-specific transplantation tolerance in mice in association with anergy of Tconvs recognizing persistently expressed alloantigens. Using murine models of fully mismatched cardiac allograft tolerance or repeated alloantigen exposure, we demonstrate that αCD154 is not sufficient and regulatory T cells (Tregs) are necessary to induce and sustain αCD154-mediated alloreactive Tconv anergy. Transient depletion of Tregs disrupted the induction of αCD154-mediated Tconv anergy, and in mice with established tolerance, Treg depletion transcriptionally and functionally reinvigorated previously anergic Tconvs. Mechanistically, Treg depletion increased IL-2 availability and IL-2R signaling in Tconvs, and exogenous IL-2 could bypass Treg-mediated control to partially restore Tconv function. Thus, the state of αCD154-mediated Tconv anergy is less cell-intrinsic than previously thought and requires Tregs to limit IL-2 availability for both its induction and its continuous enforcement. Selecting immunosuppressive drugs that preserve this Treg function may be critical for achieving stable clinical transplantation tolerance.
Förderung
- NIAID
- NIH
- American Heart Association
- American Society of Transplantation
Zitieren
APA
Cassano, A., Abbondanza, D., Wang, Y., Wu, S., McIntosh, C. M., Wang, P., Allocco, J. B., Kwan, M., Mora-Cartin, R., Craddock, E., Andrade, M. S., Chong, A. S., & Alegre, M. L. (2026). CD4+ T cell anergy in transplantation tolerance requires continuous Treg-dependent control of IL-2 availability. Journal of Clinical Investigation. https://doi.org/10.1172/jci206638
Vancouver
Cassano A, Abbondanza D, Wang Y, Wu S, McIntosh CM, Wang P, et al. CD4+ T cell anergy in transplantation tolerance requires continuous Treg-dependent control of IL-2 availability. Journal of Clinical Investigation. 2026. doi:10.1172/jci206638
BibTeX
@article{Cassano2026,
author = {Cassano, Alexandra and Abbondanza, Domenic and Wang, Ying and Wu, Shuang and McIntosh, Christine M. and Wang, Peter and Allocco, Jennifer B. and Kwan, Montserrat and Mora-Cartin, Ricardo and Craddock, Ephraim and Andrade, Michael S. and Chong, Anita S. and Alegre, Maria L.},
title = {CD4+ T cell anergy in transplantation tolerance requires continuous Treg-dependent control of IL-2 availability},
journal = {Journal of Clinical Investigation},
year = {2026},
doi = {10.1172/jci206638}
}
EUVIMED